The P16 (CDKN2A ink4a ) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 10 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA 11 methylation in cancers. It is well known that cancer cells with P16 deletion are more sensitive to palbociclib than 12 those without. However, whether P16 methylation is related to palbociclib sensitivity is not known. By
To explore the relationship between P16 methylation and the sensitivity of cancer cells to palbociclib, we 9 145 first analyzed the correlation between the IC50 levels of palbociclib in 522 cell lines and the transcription level 146 and copy number of the CDKN2A/P16 gene using public pharmacogenomics datasets [30, 31] . The analysis 147 results revealed that the palbociclib IC50 levels in these cell lines were positively correlated with the CDKN2A 148 mRNA level (r=0.3133, p<0.0001; Fig 1a) and CDKN2A copy number (r=0.2832, p<0.0001; Fig 1b) . This result 149 suggests that cancer cell lines with low or no P16 expression are more sensitive to palbociclib than those with 150 high P16 expression.
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Then, we validated the correlation in 22 cancer cell lines, which were divided into P16-unmethylated 152 (P16-U), P16-methylated (P16-M), and P16-deleted (P16-D) groups according to the results of MSP (Fig 1c) .
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We found that the IC50 values in the P16-U cell lines (n=12) were consistently higher than those in the P16-M doxycycline treatment for 2 weeks. P16 methylation was successfully induced in these P16-Dnmt cells, as 170 evidenced by MSP (Fig 2a) . qRT-PCR analysis revealed that the level of P16 expression was markedly 171 decreased in these P16-Dnmt cells (Fig 2b) . Then, these cells were treated with palbociclib at different 172 concentrations (0, 5, 10 μM), and cell viability (survival rate) was assessed. The results showed that epigenetic P16-Dnmt cells (Fig 2b) . Therefore, we further investigated whether palbociclib treatment could selectively 190 inhibit the proliferation of the P16-methylated subpopulation of P16-Dnmt cells. As expected, the population of 191 P16-methylated cells was significantly decreased by palbociclib treatment in the H661, HCC827, and BGC823
192 cell lines stably transfected with P16-Dnmt (Fig 3a) . In contrast, the P16 mRNA level was significantly 
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or control buffer for three weeks. Compared with control buffer, palbociclib significantly inhibited the growth of
